All Archives - Gilde Healthcare

Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which...

10 september 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which...

10 september 2025

Gilde Healthcare appoints Dr. Christian Stark as Group CEO of its globally operating medical technology group

The medical technology group, which includes two manufacturers of surgical instruments in the Tuttlingen region, Koscher & Würtz and Christian Diener, has appointed Dr. Christian Stark as Chief Executive Officer...

3 september 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which...

10 september 2025

Filter & zoek

Zoek:

Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level...

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor payload activity Expect to share preliminary data from the trial by early...
10 september 2025

Gilde Healthcare appoints Dr. Christian Stark as Group CEO of its globally operating medic...

The medical technology group, which includes two manufacturers of surgical instruments in the Tuttlingen region, Koscher & Würtz and Christian Diener, has appointed Dr. Christian Stark as Chief Executive Officer (CEO) with effect from September 1, 2025. Dr. Stark has more than 20 years of experience in...
3 september 2025

Gilde Healthcare kondigt succesvolle exit aan van portfoliobedrijf Novicare, een specialis...

Gilde Healthcare, de gespecialiseerde investeerder in de zorgsector, heeft een overeenkomst bereikt over de verkoop van haar Nederlandse portfoliobedrijf Novicare aan Gimv*. Novicare biedt uitbestede medische en paramedische (tele)zorg. Het bedrijf is gespecialiseerd in ouderenzorg en gehandicaptenzorg. Met actieve betrokkenheid van Gilde Healthcare heeft Novicare een aanzienlijke...
28 augustus 2025

Gilde Healthcare company SynOx Therapeutics Completes Enrollment in Registrational Trial S...

Top-Line Results from Study Evaluating Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) Expected in First Quarter of 2026.
5 augustus 2025

Gilde Healthcare company Shoulder Innovations Announces Pricing of Initial Public Offering...

Shoulder Innovations, Inc. (“Shoulder Innovations”), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $15.00 per share. In addition,...
31 juli 2025

Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for pr...

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling the initiation of a Phase I/II clinical trial in patients with primary...
9 juli 2025

Gilde Healthcare’s private equity fonds bundelt Artinis en NIRx tot wereldleider in neur...

Gilde Healthcare kondigt vandaag de gecombineerde private equity investering aan in Artinis Medical Systems (Nederland) en NIRx Medical Technologies (Duitsland/Verenigde Staten), beiden pioniers op het gebied van functionele Near-Infrared Spectroscopy (fNIRS). Door deze dubbele transactie worden twee sterk complementaire bedrijven samengebracht tot een wereldwijde koploper in fNIRS....
8 juli 2025

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Sta...

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors  Proceeds will support clinical development of lead program SB-007 in Stargardt disease   Funding will also advance a broader pipeline of genetic...
11 juni 2025

Gilde Healthcare participates in $75 Million Series D round of SpyGlass Pharma to Advance ...

SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy, addressing the need for long-term management of glaucoma and other chronic ophthalmic diseases. Gilde Healthcare joined the...
3 juni 2025
Loading...
Dit waren alle artikelen
cebfea9f84